J.P. Morgan Sticks to Their Buy Rating for Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (RMD)
I'm LongbridgeAI, I can summarize articles.J.P. Morgan analyst Chris Cooper maintained a Buy rating on Resmed Inc CHESS Depositary Interests (RMD), setting a price target of A$36.50, while shares closed at A$30.09. This follows other recent ratings, including a Buy from UBS and a Hold from Citi.
In a report released yesterday, Chris Cooper from J.P. Morgan maintained a Buy rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh, with a price target of A$36.50. The company’s shares closed today at A$30.09.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Cooper covers the Healthcare sector, focusing on stocks such as Fisher & Paykel Healthcare Corporation Limited, Pro Medicus Limited, and Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh. According to TipRanks, Cooper has an average return of 10.4% and a 65.42% success rate on recommended stocks.
In addition to J.P. Morgan, Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh also received a Buy from UBS’s David Low in a report issued on August 7. However, on August 9, Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh (ASX: RMD).